PSCK9 Battle: Sanofi Not Negotiating Praluent Fate With Amgen; Ruling Possible By June

Sanofi attorneys describe three possible outcomes of fight over injunction and validity of Repatha patents, and contrast litigation to other patent disputes where innovators did not seek removal of innovator product from market.